Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Synopsys, Inc. (SNPS) Price & Performance

Abeona Therapeutics IncTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Synopsys, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 186.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.

ABEOSNPS
Market Cap
$421.19M$78.68B
Sector
HealthTechnology
52-Week High
$7.45$625.80
52-Week Low
$4.17$372.33
Enterprise Value
$276.10M$87.04B

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS